/Companies

Cytonics

Jupiter, US · Founded 2006 · Florida corporation · 13 employees on LinkedIn

Find your way into Cytonics

Sign up to see every warm intro you have to Cytonics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cytonics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Cytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.

Founders & leadership

JBJoey Bose
Joey BoseChief Executive OfficerJoey Bose is CEO of Cytonics, where he leads development of recombinant protease inhibitors for osteoarthritis and has raised over $25 million through equity crowdfunding and private sources. He brings more than 15 years of biotech corporate development and capital raising experience.

Reported raises · per SEC filings

Form D private placements

$839K disclosed across 3 rounds · 2018–2019

▶$20KraisedJun 2019 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Joey BoseExecutive Officer
Offering amount
$450K
Amount sold
$20K
Minimum investment
$20K
Sales commissions
$1.5K
Placement agents
SI Securities, LLC
First sale
Jun 2019
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$25KraisedJun 2019 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Joey BoseExecutive Officer
Offering amount
$450K
Amount sold
$25K
Minimum investment
$20K
Sales commissions
$1.9K
Placement agents
SI Securities, LLC
First sale
Apr 2019
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$794KraisedDec 2018 · 20 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Joey BoseExecutive Officer
Offering amount
$1M
Amount sold
$794K
Minimum investment
$25K
First sale
Jun 2018
Incorporated
Corporation, Florida
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Companies working in the same space as Cytonics.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2011$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$192.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Cytonics do?
Cytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.
How much funding has Cytonics raised?
Cytonics has disclosed $839K raised across 3 rounds.
Where is Cytonics headquartered?
Cytonics is headquartered in Jupiter, US.